Roche’s Japanese Subsidiary Chugai And Korea’s JW Choongwae Gearing Up To Develop Three New Products
This article was originally published in PharmAsia News
For the first time since they established their joint-venture research center in Korea, JW and Chugai announced their goals for the development and sales of three globally competitive new products.
You may also be interested in...
SEOUL - South Korea's JW Choongwae Pharmaceutical Corp. launched its new erectile dysfunction product Zepeed (avanafil) in Korea Oct. 19, ahead of approval in the U.S
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.